Drug Search Results
More Filters [+]

LP-08

Alternative Names: lp-08, lp08, lp 08
Latest Update: 2024-04-16
Latest Update Note: News Article

Product Description

LP-08 (Lipella Pharmaceuticals, Inc., Pittsburgh, PA, USA) are therapeutic ÔÔemptyÕÕ liposomes developed for the intravesical treatment of IC. (Sourced from: https://lipella.com/wp-content/uploads/2019/03/LP08-2-luts2012.pdf)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lipella
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LP-08

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Cystitis, Interstitial

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

IC/BPS

P2

Completed

Cystitis, Interstitial

2018-06-14

22%

Recent News Events